AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged gamma delta+ Natural Killer T-like (AVM-NKT) immune cells. These AVM-NKT cells have unique immune response properties in comparison to ordinary T-cells and rapidly appear following a single AVM0703 dose. Pre-clinical and early clinical data indicate that these cells could play a significant role in several diseases and conditions.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)
AVM0703 Has Broad Applications to Treat Cancers and Autoimmune Syndromes
At AVM Biotechnology, our mission is to develop and deliver treatments that save lives and improve outcomes by unlocking the untapped potential of the body’s own immune system.
AVM Biotechnology is a clinical-stage company, founded by Theresa Deisher, Ph.D. The company is developing AVM0703, a proprietary and innovative therapeutic option for cancer and autoimmune diseases. AVM’s passion is to deliver drugs that are effective, safe, work rapidly and are accessible.
Dr. Deisher, with over 30 years of successful pharmaceutical research and development experience and holding over 47 patents, leads a team of scientists dedicated to changing what a life altering or life threatening diagnosis means to patients and their loved ones. She is guided by her personal philosophy that side effects from treatments should never be worse than the diseases themselves.